Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Choroidal blood flow changes with Macugen vs Avastin in AMD
2008-001600-23Phase 2Active
- Sponsor
- Luigi Sacco University Hospital
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in age-related macular degeneration (AMD) and Subretinal neovascularization comparing Macugen arm with Avastin arm (2 arms). Primary endpoint: Primary: Difference in choroidal blood flow between Macugen and Avastin. Started Dec 2009; status: active.
02
Drugs
pegaptanib sodiumbevacizumab
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2008-001600-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001600-23.